Clinical trials: CKD - Chronic Kidney Disease
Chronic Kidney Disease
Probiotic Supplements in Chronic Kidney Disease
This research will investigate the effect of oral probiotic supplements on renal function, uremic toxins inflammatory response, nutrition status, gastrointestinal symptoms, and QoL with Chronic kidney disease.
- Trial name
- NCT05359094
- Testing
- Probiotics
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Taichung Veterans General Hospital
Anemia; Hemodialysis Dependent Chronic Kidney Disease
Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan
For hemodialysis subjects currently receiving ESAs with anemia associated with chronic kidney disease, demonstrate non-inferiority of MT-6548 compared to darbepoetin alfa using Hb value and evaluate long-term safety of MT-6548.
- Trial name
- NCT03439137
- Testing
- MT-6548, Darbepoetin alfa
- Where
- 28 sites in Japan
- Volunteers
- 323 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Kidney Diseases, Diabetes Mellitus
Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study
This randomized controlled trail will evaluate the efficacy and safety of a simultaneous therapeutic carbohydrate restriction and treatment with the Sodium-Glucose-Transporter-2-Inhibitor dapagliflozin in comparison to the…
- Conditions
- Chronic Kidney Diseases, Diabetes Mellitus, PreDiabetes, Overweight and Obesity
- Trial name
- NCT06094231
- Testing
- Therapeutic carbohydrate restriction combined with an SGLT-2-Inhibitor
- Where
- Austria
- Volunteers
- 4 people
- Sponsor
- Department of Nephrology Clinic Ottakring Vienna
Chronic Kidney Diseases, RENAL INSUFFICIENCY, CHRONIC
Dialysis CHW Pilot
To determine the acceptability and feasibility of a community health worker intervention that assists dialysis patients with low socioeconomic status navigate community resources to address health-related social needs.
- Trial name
- NCT05998850
- Testing
- Community Health Worker Support with Resources
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Texas at Austin
End Stage Renal Disease
Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)
The main purpose is to determine the safety of Triferic iron administered via dialysate and intravenously in pediatric patients with chronic kidney disease on chronic hemodialysis (CKD-5HD).
- Trial name
- NCT04239391
- Testing
- Triferic
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 150 people
- Sponsor
- Rockwell Medical Technologies, Inc.
Type 2 Diabetes Mellitus
A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)
This study will evaluate the efficacy and safety of ertugliflozin (MK-8835/PF-04971729) in participants with Type 2 diabetes mellitus with Stage 3 Chronic Kidney Disease (CKD) who have inadequate glycemic control on background…
- Trial name
- NCT01986855
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 10 mg
- Volunteers
- 468 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Kidney Diseases, Hyperkalemia
Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.
The purpose of this proof-of-concept controlled-feeding study is to determine whether patiromer (Veltassa®, Relypsa, Inc., Redwood City, CA) can be used to maintain normal serum potassium concentrations in chronic kidney disease…
- Trial name
- NCT03183778
- Testing
- Patiromer, Research Diet Menu
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NYU Langone Health
Hyperparathyroidism, Secondary, Kidney Failure, Chronic
Hyperparathyroidism and Dialysis Adequacy in Hemodialysis Patients
This cross-sectional study aims to determine the prevalence of secondary hyperparathyroidism among end-stage renal disease patients on regular hemodialysis and to evaluate its relationship with dialysis adequacy at Assiut…
- Conditions
- Hyperparathyroidism, Secondary, Kidney Failure, Chronic, Chronic Kidney Diseases
- Trial name
- NCT07820150
- Volunteers
- 130 people
- Sponsor
- Assiut University
Chronic Kidney Diseases
miRNA in Chronic Kidney Diseases
Oxidative stress and endoplasmic reticulum (ER) stress play a key role in tubular damage in both acute kidney injury and chronic kidney disease (CKD).
- Trial name
- NCT06316284
- Where
- Croatia
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Josip Juraj Strossmayer University of Osijek
Chronic Kidney Diseases
Dapagliflozin and Renal Surrogate Outcomes in Advanced Chronic Kidney Disease
This is an investigator-led, randomized, open-label, blinded-endpoint, multicenter study that will include a total of approximately 180 subjects from 2 sites.
- Trial name
- DAPA-advKD (NCT05196347)
- Testing
- Dapagliflozin
- Where
- Taiwan
- Volunteers
- 180 people
- Sponsor
- Kaohsiung Medical University
Kidney Disease
Aranesp® Monthly Preference Study - 2
The purpose of this study was to evaluate subject preference for Aranesp® administered once monthly (i.e., every 4 weeks (Q4W)) or Procrit® administered once weekly (QW).
- Trial name
- NCT00117078
- Testing
- Aranesp®
- Sponsor
- Amgen
Vitamin D Deficiency, Vascular Calcification
Effects of Cholecalciferol on Osteoprotegerin Levels in Patients on Peritoneal Dialysis
Aim: To investigate whether cholecalciferol (4800 U/daily) or placebo for 16 weeks reduces proteins levels associated with vascular calcification (osteoprotegerin, osteopontin, osteocalcin) in patients treated with peritoneal…
- Conditions
- Vitamin D Deficiency, Vascular Calcification, Renal Insufficiency, End Stage Renal Failure on Dialysis
- Trial name
- NCT02598635
- Testing
- Cholecalciferol
- Where
- Mexico
- Volunteers
- 58 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Chronic Kidney Diseases
Impact of Dapagliflozin on Intestinal Microbiota Composition and on the Metabolites Derived From the Intestinal Microbiota in Non-diabetic Chronic Renal Failure Patients
Chronic kidney disease (CKD) is a common disease affecting 10-12% of the adult population and characterize with high-risk cardiovascular morbidity and mortality with progression of CKD.
- Trial name
- DAPA-GUT (NCT05965440)
- Testing
- impact of Dapagliflozin on Intestinal Microbiota on chronic renal failure patients
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Diabetes, Renal Insufficiency, Chronic
PK and PD of YG1699 in CKD Patients With Diabetes
The goal of this clinical trial is to learn PK and PD of YG1699 in patients with diabetes and renal dysfuction. Participants will: Take YG1699 or a placebo every day for 8 days. Visit the clinic 7 times for checkups and tests.
- Conditions
- Diabetes, Renal Insufficiency, Chronic, Hemodialysis
- Trial name
- NCT06648876
- Testing
- YG1699
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Chronic Kidney Diseases
Uremic Toxins and Outcomes in Chronic Kidney Disease
The aim of this cohort study is: To investigate the etiology and epidemiology of comorbidities in CKD; To find out risk factors associated with the mortality of CKD; To find out uremic toxins which are related to the mortality…
- Trial name
- NCT03711617
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Chronic Kidney Disease
A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
The purpose of this study is to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease.
- Trial name
- Dapa-CKD (NCT03036150)
- Testing
- Dapagliflozin
- Where
- 390 sites in United States, Argentina and 19 more
- Volunteers
- 4,304 people
- Sponsor
- AstraZeneca
Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging
The routine administration of 75 mg of intravenous aminophylline in patients with severe chronic kidney disease undergoing a nuclear stress test with regadenoson (Lexiscan®) can reduce or eliminate the incidence of diarrhea and…
- Trial name
- ASSUAGE-CKD (NCT01336140)
- Testing
- Aminophylline
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Rush University Medical Center
Chronic Kidney Diseases, Dialysis; Complications
Flaxseed Oil and Pomegranate Extract on Inflammation, Lipid Profile and Nutritional Status of Hemodialysis Patients
Nutritional and metabolic alterations in patients with chronic kidney disease (CKD) such as inflammation, oxidative stress, dyslipidemia, and poor nutritional status which associate with poor clinical outcome can potentially be…
- Conditions
- Chronic Kidney Diseases, Dialysis; Complications, Inflammation, Lipid Metabolism Disorders
- Trial name
- NCT05564676
- Testing
- flaxseed oil and pomegranate dry extract, sunflower oil and microcrystalline cellulose
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Santa Catarina Federal University
Diabetes Mellitus, Type 2
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
The primary purpose of this research study is to determine the cardiovascular and renal effectiveness and safety of empagliflozin compared to dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with Type 2 Diabetes Mellitus…
- Trial name
- NCT05465317
- Testing
- Empagliflozin, Dipeptidyl Peptidate-4 inhibitors
- Where
- United States
- Volunteers
- 62,197 people
- Sponsor
- Boehringer Ingelheim
Non-diabetic Chronic Kidney Disease
Vascular Effects of SGLT2i in Non-diabetic CKD
Empagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), is a novel diabetic medication that reduces the risk of progression of chronic kidney disease (CKD) and heart failure and improves exercise tolerance regardless…
- Trial name
- EMPA-CKD (NCT07060417)
- Testing
- Empagliflozin
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- VA Office of Research and Development
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.